These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36848017)

  • 1. Development and Preliminary Validation of an Instrument to Measure Symptoms and Impacts in Patients with Proliferative Diabetic Retinopathy.
    Rofail D; Sherman S; Hartford C; Levine A; Baldasaro J; Marquis P; Rao R; Do DV
    Adv Ther; 2023 Apr; 40(4):1773-1786. PubMed ID: 36848017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Patient Experience with Diabetic Retinopathy: Qualitative Analysis of Patients with Proliferative Diabetic Retinopathy.
    Sherman SA; Rofail D; Levine A; Hartford CR; Baldasaro J; Marquis P; Rao R; Do DV
    Ophthalmol Ther; 2023 Feb; 12(1):431-446. PubMed ID: 36460939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of diabetic retinopathy on vision-specific function.
    Lamoureux EL; Tai ES; Thumboo J; Kawasaki R; Saw SM; Mitchell P; Wong TY
    Ophthalmology; 2010 Apr; 117(4):757-65. PubMed ID: 20122736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
    Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
    Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term visual outcome in proliferative diabetic retinopathy patients after panretinal photocoagulation.
    Dogru M; Nakamura M; Inoue M; Yamamoto M
    Jpn J Ophthalmol; 1999; 43(3):217-24. PubMed ID: 10413257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different lasers and techniques for proliferative diabetic retinopathy.
    Moutray T; Evans JR; Lois N; Armstrong DJ; Peto T; Azuara-Blanco A
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD012314. PubMed ID: 29543992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
    Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
    JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The functional burden of diabetic retinopathy in the United States.
    Nagda D; Mitchell W; Zebardast N
    Graefes Arch Clin Exp Ophthalmol; 2021 Oct; 259(10):2977-2986. PubMed ID: 33914161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of a New Diabetic Retinopathy Knowledge and Attitudes Questionnaire in People with Diabetic Retinopathy and Diabetic Macular Edema.
    Fenwick EK; Man REK; Gan ATL; Aravindhan A; Tey CS; Soon HJT; Ting DSW; Yeo SIY; Lee SY; Tan G; Wong TY; Lamoureux EL
    Transl Vis Sci Technol; 2020 Sep; 9(10):32. PubMed ID: 33062395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Factors Associated with Vision and Edema Outcomes.
    Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Melia M; Chen E; Pavlica MR; Jampol LM;
    Ophthalmology; 2018 Nov; 125(11):1776-1783. PubMed ID: 29980333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
    JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
    Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
    Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of the Pulmonary Arterial Hypertension-Symptoms and Impact (PAH-SYMPACT®) questionnaire: a new patient-reported outcome instrument for PAH.
    McCollister D; Shaffer S; Badesch DB; Filusch A; Hunsche E; Schüler R; Wiklund I; Peacock A;
    Respir Res; 2016 Jun; 17(1):72. PubMed ID: 27301413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
    Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
    JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
    Alagorie AR; Velaga S; Nittala MG; Yu HJ; Wykoff CC; Sadda SR
    Ophthalmol Retina; 2021 May; 5(5):409-419. PubMed ID: 32882447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.
    Nicholson L; Ramu J; Chan EW; Bainbridge JW; Hykin PG; Talks SJ; Sivaprasad S
    JAMA Ophthalmol; 2019 Jun; 137(6):626-631. PubMed ID: 30973596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ).
    Hareendran A; Skalicky A; Mannix S; Lavoie S; Desai P; Bayliss M; Thach AV; Mikol DD; Buse DC
    Headache; 2018 Nov; 58(10):1612-1628. PubMed ID: 30374958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial.
    Halim S; Nugawela M; Chakravarthy U; Peto T; Madhusudhan S; Lenfestey P; Hamill B; Zheng Y; Parry D; Nicholson L; Greenwood J; Sivaprasad S
    JAMA Ophthalmol; 2021 May; 139(5):501-507. PubMed ID: 33704351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
    Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
    JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.